




Contents lists available at [ScienceDirect](#)

International Journal for Parasitology: Drugs and Drug Resistance

journal homepage: www.elsevier.com/locate/ijpddr



Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]

Philip T. LoVerde^{a,b,*}, Sevan N. Alwan^a, Alexander B. Taylor^a, Jayce Rhodes^c,
Frédéric D. Chevalier^d, Timothy Jc Anderson^e, Stanton F. McHardy^c

^a Departments of Biochemistry and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA

^b Pathology and Laboratory Medicine, The University of Texas Health Science Center, San Antonio, TX, USA

^c Center for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, San Antonio, TX, USA

^d Program in Host-Pathogen Interactions, Texas Biomedical Research Institute, San Antonio, TX, USA

^e Program in Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX, USA

The authors regret that the acknowledgements of SNA were funded of the article.
by SABER IRACDA program 2k12GM111726 was inadvertently left out

DOI of original article: <https://doi.org/10.1016/j.ijpddr.2021.05.002>.

* Corresponding author. Departments of Biochemistry and Structural Biology, USA.

E-mail address: loverde@uthscsa.edu (P.T. LoVerde).

<https://doi.org/10.1016/j.ijpddr.2022.01.003>

Available online 19 January 2022

2211-3207/© 2022 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).